Jonsson Comprehensive Cancer Center: Prostatic Neoplasms trials

The registry lists 68 Prostatic Neoplasms studies with Jonsson Comprehensive Cancer Center as lead sponsor. 14 are open to participants now and 4 have results posted.

Early Phase 1 6Phase 1 11Phase 2 19Phase 3 3No phase 29(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Focal Radiation Therapy (HDR-Brachytherapy) for the Treatment of Prostate CancerRecruitingNCT07468903Not applicable
• Vascular Optimized Radiotherapy Tuned to Critical Structures for Erectile Function Using High-Precision X-Ray TreatmentRecruitingNCT07293585Phase 3
• Image-Guidance and Online Adaptation With Stereotactic Body Radiation Therapy for the Treatment of Localized Prostate Cancer, MANTICORE TrialRecruitingNCT07276438Not applicable
• An Investigational Scan (Flotufolastat F 18 PET/CT) for Detecting Residual or Recurrent Disease in Patients Who Completed Focal Therapy for Prostate Cancer.RecruitingNCT07185165Phase 2
• Comparing a New PSMA Imaging Agent to MRI for Detecting Prostate Cancer, BEACON TrialRecruitingNCT07164027Early Phase 1
• Prostate Cancer Postoperative Stereotactic Body Radiotherapy With Adaptive Technology for Minimizing ToxicityRecruitingNCT07077239
• Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA TrialRecruitingNCT06288113Phase 2
• Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT)RecruitingNCT06216249Phase 2
• Hormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients With Prostate Cancer, HEATWAVE TrialRecruitingNCT06067269Phase 2
• Image-Guided Biopsies to Identify Mechanisms of Resistance in Patients With Metastatic Castration Resistant Prostate Cancer Treated With 177Lu-PSMA Radioligand TherapyRecruitingNCT05398302Phase 1
• High Dose-Rate Brachytherapy and Stereotactic Body Radiotherapy for the Treatment of Prostate AdenocarcinomaRecruitingNCT04945642Not applicable
• 99mTc-PSMA-I&S Biodistribution in Patients With Prostate CancerRecruitingNCT04857502Early Phase 1
• Integrating Quantitative MRI and Artificial Intelligence to Improve Prostate Cancer ClassificationRecruitingNCT04765150
• Active Surveillance for Cancer of the Prostate (ASCaP)RecruitingNCT00949819
• Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or ProstateActive, not recruitingNCT03582475Phase 1Results posted
• Stereotactic Body Radiation Therapy in Treating Patients With High-Risk Prostate Cancer Undergoing SurgeryCompletedNCT02830165Not applicableResults posted
• Green Tea, Black Tea, or Water in Treating Patients With Prostate Cancer Undergoing SurgeryCompletedNCT00685516Not applicableResults posted
• Paclitaxel and Carboplatin in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone TherapyCompletedNCT00049257Phase 2Results posted
• Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic CancersActive, not recruitingNCT07118176Phase 1
• Computed Tomography-Guided Stereotactic Body Radiation Therapy With Intrafraction Motion Monitoring for the Treatment of Localized Prostate Cancer, ILLUSION TrialActive, not recruitingNCT06995053Not applicable
• Focal Laser Ablation of Prostate Cancer: A Feasibility Study Using MRI/US Image Fusion for GuidanceTerminatedNCT06047509Not applicable
• 177-Lutetium-PSMA Before Stereotactic Body Radiotherapy for the Treatment of Oligorecurrent Prostate Cancer, The LUNAR StudyActive, not recruitingNCT05496959Phase 2
• Image-Guided (68Ga-PSMA-11 PET/CT) Prostate Biopsy for the Diagnosis of Prostate Cancer in Men With Prior Negative/Inconclusive BiopsyActive, not recruitingNCT05160597Early Phase 1
• 68Ga-PSMA-11 PET/CT for the Diagnosis of Bone Metastases in Patients With Prostate Cancer and Biochemical Progression During Androgen Deprivation TherapyTerminatedNCT04928820Phase 2
• Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for the Treatment of Prostate Cancer With Rising PSA After Radical ProstatectomyActive, not recruitingNCT04915508Phase 2
• Germline DNA-Based Radiosensitivity Biomarker Influence on Toxicity Following Prostate Radiotherapy, GARUDA TrialActive, not recruitingNCT04624256Not applicable
• Randomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate CancerTerminatedNCT04457245Phase 3
• Prospective Exploratory Study of FAPi PET/CT in Prostate Cancer With Histopathology ValidationActive, not recruitingNCT04457232Phase 1
• Focal Radiation Therapy for the Treatment of Low or Intermediate-Risk Prostate CancerWithdrawnNCT04399824Not applicable
• Expanded Access Protocol of 68Ga-PSMA-11 for PET ImagingApproved for marketingNCT04348682
• Focal Laser Ablation of Prostate CancerCompletedNCT04305925Early Phase 1
• Micro-Ultrasound for the Detection and Localization of Prostate Cancer Tumors in Patients Undergoing Radical ProstatectomyActive, not recruitingNCT04299620Not applicable
• Impact of Monosodium Glutamate on 68GA-PSMA-11, PET Imaging Biodistribution in Patients With Prostate CancerCompletedNCT04282824Early Phase 1
• Effect of Androgen Receptor Signaling Inhibitors on 68Ga-PSMA-11 PET/CT Imaging in Patients With Castration-Resistant Prostate CancerTerminatedNCT04279561Phase 1
• 68GA-PSMA-11 PET/CT Scan in Impacting Treatment Strategies for Patients With Prostate CancerCompletedNCT04050215Phase 2
• Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate CancerActive, not recruitingNCT03902951Phase 2
• Image-Guided Biopsies in Identifying Mechanisms of Resistance in Participants With Metastatic Castration Resistant Prostate Cancer Undergoing Radioligand TherapyWithdrawnNCT03596710Not applicable
• Multicenter Randomized Trial of 68Ga-PSMA-11 PET/CT Based SRT After Radical ProstatectomyActive, not recruitingNCT03582774Phase 3
• Gallium Ga 68-labeled PSMA-11 PET/CT and Fluciclovine F18 PET/CT in Imaging Participants With Recurrent Prostate Cancer After SurgeryCompletedNCT03515577Phase 2
• Hemi-Gland Cryoablation for Prostate Cancer at UCLACompletedNCT03503643
• Compassionate Use: Progressive Metastatic Castrate Resistant Prostate Cancer; Monotherapy Treatment With TrametinibNo longer availableNCT03386071
• 68Ga-PSMA-11 PET/CT in Imaging Patients With Intermediate or High Risk Prostate Cancer Before SurgeryCompletedNCT03368547Not applicable
• Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate CancerActive, not recruitingNCT02881242Phase 2
• C11 Sodium Acetate PET/CT Imaging of PCaNo longer availableNCT02826395
• Prospective Assessment of Image Registration for the Diagnosis of Prostate CancerCompletedNCT02425228
• Focal Laser Ablation of Prostate TissueCompletedNCT02357121Early Phase 1
• Stereotactic Body Radiation Therapy in Treating Patients With Localized High-Risk Prostate CancerActive, not recruitingNCT02296229Not applicable
• Use of Laser Interstitial Thermal Therapy in the Focal Treatment of Localized Prostate CancerCompletedNCT02224911
• Low-Fat Diet and Fish Oil in Men on Active Surveillance for Prostate CancerActive, not recruitingNCT02176902Not applicable
• Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate CancerActive, not recruitingNCT01990196Phase 2
• Effect of Quercetin on Green Tea Polyphenol Uptake in Prostate Tissue From Patients With Prostate Cancer Undergoing SurgeryCompletedNCT01912820Phase 1
• Internal Radiation Therapy in Treating Patients With Low-Risk Prostate CancerWithdrawnNCT01859689Phase 2
• Hypo-fractionated Stereotactic Body Radiotherapy for Localized Prostate CancerCompletedNCT01059513
• Low-Fat Fish Oil Diet for Prostate Cancer PreventionCompletedNCT00798876Not applicable
• Clinical Study of SU011248 in Subjects With High Risk Prostate Cancer Who Have Elected to Undergo Radical ProstatectomyCompletedNCT00790595Phase 1
• Informed Decision-Making Regarding Prostate Specific Antigen (PSA) Screening in 50-70 Year Old Latino MenCompletedNCT00761124Not applicable
• A Study Of the Effectiveness Of Pomegranate Pills in Men With Prostate Cancer Before ProstatectomyCompletedNCT00719030Not applicable
• T-Cell Response in Patients Receiving Trastuzumab and/or Chemotherapy for HER2-Positive Solid TumorsCompletedNCT00433407Not applicable
• Docetaxel and Erlotinib in Treating Older Patients With Prostate CancerCompletedNCT00087035Phase 2
• Neoadjuvant CCI-779 Followed By Radical Prostatectomy in Treating Patients With Newly Diagnosed Prostate Cancer Who Have a High Risk of RelapseCompletedNCT00071968Phase 2
• Pomegranate Juice in Treating Patients With Recurrent Prostate CancerCompletedNCT00060086Not applicable
• Monoclonal Antibody Therapy in Treating Patients With Prostate CancerCompletedNCT00054574Phase 2
• Biological Therapy in Treating Patients With Prostate CancerCompletedNCT00039299Phase 1
• SU006668 in Treating Patients With Advanced Solid TumorsStatus unknownNCT00024063Phase 1
• Low-Fat, High-Fiber Diet Compared to a Standard Diet in Treating Patients With Prostate CancerCompletedNCT00020995Phase 2
• CCI-779 in Treating Patients With Prostate CancerCompletedNCT00012142Phase 2
• Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone TherapyStatus unknownNCT00005992Phase 1
• Monoclonal Antibody ABX-EGF in Treating Patients With Renal (Kidney), Prostate, Pancreatic, Non-Small Cell Lung, Colon or Rectal, Esophageal, or Gastroesophageal Junction CancerCompletedNCT00004879Phase 1